MannKind Corporation (MNKD)
| Market Cap | 1.33B -17.6% |
| Revenue (ttm) | 413.37M +31.7% |
| Net Income | -74.82M |
| EPS | -0.27 |
| Shares Out | 321.64M |
| PE Ratio | n/a |
| Forward PE | 77.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,686,713 |
| Open | 4.150 |
| Previous Close | 4.160 |
| Day's Range | 4.080 - 4.180 |
| 52-Week Range | 2.230 - 6.510 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 8.33 (+101.77%) |
| Earnings Date | Nov 5, 2026 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company’s commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult... [Read more]
Financial Performance
In 2025, MannKind's revenue was $348.97 million, an increase of 22.23% compared to the previous year's $285.50 million. Earnings were $5.86 million, a decrease of -78.75%.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price target is $8.33, which is an increase of 101.77% from the latest price.
News
MannKind to Participate in Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind price target raised to $10 from $8 at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders raised the firm’s price target on MannKind (MNKD) to $10 from $8 and keeps an Overweight rating on the shares. MannKind’s Q3 results highlighted…
MannKind reports Q3 adjusted EPS (1c), consensus (1c)
Reports Q3 revenue $101.87M, consensus $108.54M. “The third quarter marked an important transition for MannKind (MNKD) as we shifted from delivering on three major catalysts to executing against them,...
MannKind Earnings Call Transcript: Q3 2026
Q3 revenue rose 24% YoY as commercial products became the largest revenue source, led by FUROSCIX and pediatric Afrezza momentum. Management expects Q4 profitability and annual profitability in 2027, with INFLO-2 data targeted for H1 2028.
MannKind Earnings release: Q3 2026
MannKind released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
MannKind Quarterly report: Q3 2026
MannKind has published its Q3 2026 quarterly earnings report on November 5, 2026.
MannKind Slides: Q3 2026
MannKind has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market...
MannKind Transcript: Chardan's 10th Annual Healthcare Conference
Inhaled nintedanib Phase II is underway, while commercial growth is expected from FUROSCIX ReadyFlow and TYVASO DPI. GenRALD may enter human testing by year-end 2026, and management said current cash can fund growth without a financing.
MannKind initiated with a Buy at Chardan
Chardan analyst Andreas Argyrides initiated coverage of MannKind (MNKD) with a Buy rating and $10 price target The drug-device company’s revenue mix is shifting away from Tyvaso DPI, notes the…
MannKind to Participate in the Chardan Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a ...
Liquidia ruling has positive read-through for MannKind Tyvaso DPI, says Truist
Liquidia’s (LQDA) Yutrepia faces a Delaware court finding of infringement of United Therapeutics’ (UTHR) ‘327 patent, pressuring Liquidia shares but providing a positive read-through for MannKind’s (M...
MannKind Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Three major catalysts in 2026—Afrezza pediatric approval, FUROSCIX ReadyFlow launch, and positive IPF 201 data—set the stage for focused commercial execution and pipeline advancement. Early adoption metrics are strong, and 2027 will emphasize sales growth and development milestones.
MannKind management to meet with Cantor
Meeting to be held in Boston on September 17 hosted by Cantor.
MannKind and Rose Pharma sign licensing and collaboration agreement
MannKind (MNKD) and Rose Pharma announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere for weight management. ROSE-010 is an investiga...
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalti...
MannKind to Present at Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind price target lowered to $13 from $14 at Wells Fargo
Wells Fargo lowered the firm’s price target on MannKind (MNKD) to $13 from $14 and keeps an Overweight rating on the shares. The firm believes that good execution on product…
MannKind reports Q2 EPS (6c), consensus 2c
Reports Q2 revenue $109.37M, consensus $108.8M. “This was a transformative period for MannKind (MNKD), during which we delivered all three major catalysts we set out to achieve in 2026,” said…
MannKind Earnings Call Transcript: Q2 2026
Q2 revenue grew 43% year-over-year, driven by strong Afrezza and FUROSCIX sales, with pediatric Afrezza launch and FUROSCIX ReadyFlow approval marking key milestones. Guidance for FUROSCIX remains $110M–$120M, with margin expansion expected as ReadyFlow ramps.
MannKind Earnings release: Q2 2026
MannKind released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
MannKind Quarterly report: Q2 2026
MannKind has published its Q2 2026 quarterly earnings report on August 5, 2026.
MannKind Slides: Q2 2026
MannKind has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza ® following FDA approval FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and ...
MannKind price target raised to $14 from $11 at Wells Fargo
Wells Fargo raised the firm’s price target on MannKind (MNKD) to $14 from $11 on higher Furoscix and ‘201 probability of success, while keeping an Overweight rating on the shares.